These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30412076)

  • 1. Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials.
    Zhang YJ; Han SL; Sun XF; Wang SX; Wang HY; Liu X; Chen L; Xia L
    Medicine (Baltimore); 2018 Oct; 97(43):e12843. PubMed ID: 30412076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
    Levine MJ
    Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis.
    Zhong X; Lai D; Ye Y; Yang X; Yu B; Huang Y
    Eur J Clin Pharmacol; 2016 Jun; 72(6):655-63. PubMed ID: 26832915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
    Devi R; Mali G; Chakraborty I; Unnikrishnan MK; Abdulsalim S
    Postgrad Med; 2017 Apr; 129(3):382-392. PubMed ID: 27841714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
    Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
    Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials.
    Yabe D; Yasui A; Ji L; Lee MK; Ma RCW; Chang TJ; Okamura T; Zeller C; Kaspers S; Lee J; Kohler S; Seino Y
    J Diabetes Investig; 2019 Mar; 10(2):418-428. PubMed ID: 30099847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
    Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
    Dailey GE
    Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients.
    Babar M; Hussain M; Ahmad M; Akhtar L
    J Ayub Med Coll Abbottabad; 2021; 33(2):188-191. PubMed ID: 34137526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
    Liakos A; Karagiannis T; Athanasiadou E; Sarigianni M; Mainou M; Papatheodorou K; Bekiari E; Tsapas A
    Diabetes Obes Metab; 2014 Oct; 16(10):984-93. PubMed ID: 24766495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
    Kaku K; Haneda M; Tanaka Y; Lee G; Shiki K; Miyamoto Y; Solimando F; Lee J; Lee C; George J
    Diabetes Obes Metab; 2019 Jan; 21(1):136-145. PubMed ID: 30091172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®.
    Zinman B; Inzucchi SE; Wanner C; Hehnke U; George JT; Johansen OE; Fitchett D;
    Diabetologia; 2018 Jul; 61(7):1522-1527. PubMed ID: 29713728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
    Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
    Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study rationale and design of a study of EMPAgliflozin's effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial.
    Gohari S; Reshadmanesh T; Khodabandehloo H; Fathi M; Ahangar H; Arsang-Jang S; Ismail-Beigi F; Ghanbari S; Dadashi M; Muhammadi MJ; Gohari S; Ghaffari S
    BMC Cardiovasc Disord; 2021 Jun; 21(1):318. PubMed ID: 34193056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES].
    Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):472-9. PubMed ID: 26638450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.